Participants
stroke, dementia, ’s disease, impaired memory functions, diabetes
STROKE, TYPE 2 DIABETES, DIABETES
A total of 110 participants with newly diagnosed diabetes and fasting blood sugar level ≥126 mg/dL were invited to take part in the study. They were randomly assigned into two groups: those receiving training on the patient-centered intervention program (n = 55, intervention group) and the control group (n = 55, control group). The intervention was co-developed with advice from patients with diabetes who were neither included in the study nor in the interpretation or writing of findings.The following inclusion criteria were applied: (i) adult participants above 18 years of age with newly diagnosed Type 2 diabetes; (ii) participants willing to take part in the study; (iii) participants able to provide informed written or verbal consent. Exclusion criteria were: (i) participants self-reporting to have significantly impaired memory functions and other conditions that affect the capacity to give consent such as dementia, stroke, Huntingdon’s disease, etc.; (ii) participants with significant mobility issues; (iii) participants who were unable to provide informed consent; (iv) more than one participant from the same family.Participants were treated in accordance with the applicable ethical guidelines that followed the tenets of the Helsinki Declaration. Information that could identify individual participants during or after data collection was not recorded. Participants were assured that they did not have to take part in the study or if they wished to drop out of the study once they decided to take part, it would not affect any care or treatment they would otherwise receive from their doctor or hospital. All participants took their prescribed treatment from the doctor regardless of which group they belonged to.